Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Levofloxacin and ciprofloxacin in vitro activities against 4,003 clinical bacterial isolates collected in 24 Italian laboratories.

Literature DB >> 12543701

Levofloxacin and ciprofloxacin in vitro activities against 4,003 clinical bacterial isolates collected in 24 Italian laboratories.

Giovanni Pietro Gesu¹, Federico Marchetti, Laura Piccoli, Annalisa Cavallero.

Abstract

Levofloxacin showed comparable in vitro susceptibility to ciprofloxacin among Enterobacteriaceae, Pseudomonas aeruginosa, enterococci, and Staphylococcus aureus, while greater susceptibility was observed in Stenotrophomonas maltophilia and Staphylococcus epidermidis, mainly when oxacillin resistant. The susceptibility of Streptococcus pneumoniae to levofloxacin reached 99%.

Entities: Chemical Species

Mesh：

Substances：

Year: 2003 PMID： 12543701 PMCID： PMC151783 DOI： 10.1128/AAC.47.2.816-819.2003

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

15 in total

1. In vitro activity of levofloxacin against coagulase-positive and -negative staphylococci.

Authors: V Cafiso; C Messina; M Santagati; F Campanile; G Bonfiglio; S Stefani
Journal: Drugs Exp Clin Res Date: 2001

2. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999.

Authors: A C Gales; R N Jones; J Turnidge; R Rennie; R Ramphal
Journal: Clin Infect Dis Date: 2001-05-15 Impact factor: 9.079

3. Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. French and Portuguese ICU Study Groups.

Authors: H Hanberger; J A Garcia-Rodriguez; M Gobernado; H Goossens; L E Nilsson; M J Struelens
Journal: JAMA Date: 1999-01-06 Impact factor: 56.272

4. Levofloxacin in vitro activity and time-kill evaluation of Stenotrophomonas maltophilia clinical isolates.

Authors: G Bonfiglio; C Cascone; C Azzarelli; V Cafiso; F Marchetti; S Stefani
Journal: J Antimicrob Chemother Date: 2000-01 Impact factor: 5.790

5. Activity of levofloxacin and ciprofloxacin against urinary pathogens.

Authors: L Drago; E De Vecchi; B Mombelli; L Nicola; M Valli; M R Gismondo
Journal: J Antimicrob Chemother Date: 2001-07 Impact factor: 5.790

6. Is levofloxacin as active as ciprofloxacin against Pseudomonas aeruginosa?

Authors: G Bonfiglio
Journal: Chemotherapy Date: 2001 Jul-Aug Impact factor: 2.544

7. In vitro activity of levofloxacin against gram-positive bacteria.

Authors: M P Montanari; M Mingoia; F Marchetti; P E Varaldo
Journal: Chemotherapy Date: 1999 Nov-Dec Impact factor: 2.544

8. Evaluation of current activities of fluoroquinolones against gram-negative bacilli using centralized in vitro testing and electronic surveillance.

Authors: D F Sahm; I A Critchley; L J Kelly; J A Karlowsky; D C Mayfield; C Thornsberry; Y R Mauriz; J Kahn
Journal: Antimicrob Agents Chemother Date: 2001-01 Impact factor: 5.191

9. Comparison of E test and agar dilution for antimicrobial susceptibility testing of Stenotrophomonas (Xanthomonas) maltophilia.

Authors: J D Yao; M Louie; L Louie; J Goodfellow; A E Simor
Journal: J Clin Microbiol Date: 1995-05 Impact factor: 5.948

10. Italian survey on comparative levofloxacin susceptibility in 334 clinical isolates of Pseudomonas aeruginosa.

Authors: B Segatore; D Setacci; M Perilli; N Franceschini; A De Santis; F Marchetti; G Amicosante
Journal: Antimicrob Agents Chemother Date: 1999-02 Impact factor: 5.191

5 in total

1. Differential effects of levofloxacin and ciprofloxacin on the risk for isolation of quinolone-resistant Pseudomonas aeruginosa.

Authors: Keith S Kaye; Zeina A Kanafani; Ashley E Dodds; John J Engemann; Stephen G Weber; Yehuda Carmeli
Journal: Antimicrob Agents Chemother Date: 2006-06 Impact factor: 5.191

2. Can levofloxacin be a useful alternative to trimethoprim-sulfamethoxazole for treating Stenotrophomonas maltophilia bacteremia?

Authors: Sun Young Cho; Cheol-In Kang; Jungok Kim; Young Eun Ha; Doo Ryeon Chung; Nam Yong Lee; Kyong Ran Peck; Jae-Hoon Song
Journal: Antimicrob Agents Chemother Date: 2013-10-14 Impact factor: 5.191